Insights from 2023 SABCS
E

SABCS 2023 Insights: "HER2CLIMB-05 Trial - Tucatinib or Placebo in Combination With Trastuzumab & Pertuzumab as Maintenance Therapy for HER2+ mBC"

By Insights from 2023 SABCS FEATURING Erika Hamilton
By Insights from 2023 SABCS FEATURING Erika Hamilton
243 views
December 19, 2023
0 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
London Breast Meeting

London Breast Meeting 2024

Wed, Sep 4, 2024
12:35
Insights from 2023 SABCS

SABCS 2023 Summary: "What Is the Appropriate 1L Therapy for ER+…

Feat. S. Tolaney, H. Rugo
14:16
Dana-Farber Cancer Institute

Year in Review: Breast Cancer

Feat. P. Tarantino
17:20
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Summary: "Top 5 Breast Cancer Studies Including KEYNO…

Feat. P. Tarantino
57:44
Vogl, NY

Vogl,NY on How to Ask Good Questions at Medical Meetings

Feat. S. Vogl
49:07
SABCS 2022 Conference Coverage

SABCS 2022 Expert Panel Discussion: Practice-Changing Updates

Feat. J. O'Shaughnessy, S. Tolaney, S. Hurvitz, H. Rugo
07:50
Oncology Data Advisor

ESMO 2023 Insights: "Real-World Use Patterns, Effectiveness, &a…

Feat. K. Kalinsky
22:34
Dana-Farber Cancer Institute

What's New in Breast Cancer?

Feat. S. Tolaney
17:35
Insights from 2023 SABCS

SABCS 2023 Summary: "Top 5 Studies Including KATHERINE & HE…

Feat. P. Tarantino
30:46
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Panel Discussion: "Metastatic Breast Cancer"

Feat. S. Tolaney, H. Rugo
24:10
Keck School of Medicine of USC

CDK4/6 Inhibitors in Breast Cancer: 2024 Update

Feat. R. O'Regan
21:37
Dana-Farber Cancer Institute

Standard Treatments for HR+/HER2- mBC in 2023

Feat. S. Sammons
27:01
Scripps MD Anderson Cancer Center Clinical Hematology & Oncology 2024

CDK4/6 Inhibitor Therapy in Early-Stage HR+/HER2- BC

Feat. S. Sammons
29:40
Insights from 2023 SABCS

Year in Review: Metastatic Breast Cancer

Feat. M. Mac Gregor
12:21
Insights from 2023 SABCS

SABCS 2023 Insights: "How to Treat TNBC"

Feat. P. Sharma
03:24
ecancer

SABCS 2022 EMERALD Phase 3 Trial: Elacestrant and PFS in ER+/HER2- m…

Feat. V. Kaklamani
02:35
Integrity Continuing Education

SABCS 2023 Summary: "monarchE & NATALEE Trials - Adjuvant T…

Feat. A. Bardia
13:23
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Summary: "A Pooled Analysis of T-DXd for HER2+ mBC Wi…

Feat. S. Hurvitz
20:42
Total Health

2022 Updates in TNBC

Feat. I. Schlam
20:16
University of Colorado Cancer Center

Updated NCCN Guidelines for HR+/HER2- mBC: Treatment Options in 1L S…

Feat. V. Borges
18:11
Nagi El Saghir

ABC7 2023 International Consensus Guidelines: Select Guidelines for …